Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China

Table 5 Later period major complications after operation between hepatitis B virus core antibody positive liver graft recipients and hepatitis B virus core antibody negative liver graft recipients (beyond 30 d post liver transplantation) %

Major complication	Before propensity matching			After propensity matching
	Anti-HBc+ (n = 230)	Anti-HBc- (n = 841)	P value	Anti-HBc+ (n = 210)	Anti-HBc- (n = 210)	P value
Acute rejection	11.30 (26/230)	11.05 (93/841)	0.91	9.52 (20/210)	8.10 (17/210)	0.60
Chronic rejection	0.87 (2/230)	0.95 (8/841)	> 0.9	0.95 (2/210)	0.95 (2/210)	1.00
GVHD	0.43 (1/230)	0.59 (5/841)	> 0.9	0.47 (1/210)	0.47 (1/210)	1.00
Biliary complications	9.56 (22/230)	9.15 (77/841)	0.85	7.14 (15/210)	10.95 (23/210)	0.17
Hepatic artery stenosis/embolism	0.87 (2/230)	0.71 (6/841)	0.68	0.95 (2/210)	2.38 (5/210)	0.45
Portal vein stenosis/embolism	0.87 (2/230)	1.78 (15/841)	0.55	0.95 (2/210)	0.95 (2/210)	1.00
Outflow tract stenosis/embolism	0.43 (1/230)	0.71 (6/841)	> 0.9	0.47 (1/210)	0.47 (1/210)	1.00
Tumor recurrence	5.65 (13/230)	4.52 (38/841)	0.51	4.76 (10/210)	6.19 (13/210)	0.52
CMV infection	0.87 (2/230)	0.83 (7/841)	> 0.9	0.95 (2/210)	1.90 (4/210)	0.68
Opportunistic infection	2.17 (5/230)	1.43 (12/841)	0.38	1.43 (3/210)	2.38 (5/210)	0.72
Diabetes mellitus	7.82 (18/230)	7.97 (67/841)	0.94	7.14 (15/210)	4.76 (10/210)	0.3
Hypertension	4.78 (11/230)	3.57 (30/841)	0.39	3.33 (7/210)	2.38 (5/210)	0.77
Hyperlipemia	0.43 (1/230)	0.95 (8/841)	0.69	0.47 (1/210)	1.90 (4/210)	0.37

Differences between rates were tested by Chi square test or Fisher exact test, if appropriate. CMV: Cytomegalovirus; GVHD: Graft-vs-host disease.